Drugs & Pharmaceuticals

During his State of the Union Address last week, President Biden announced a plan to make it easier for people to get access to the new antiviral drug Paxlovid.

The White House just announced a "test to treat" program that is an excellent, but not perfect, way of dealing with future COVID infections.

Sometimes you just run across a study or paper that is really clever. Although I've never given much (make that any) thought to the importance of drug palatability as it pertains to compliance, this is where the clever part comes in.

I don't know about you, but I started losing interest in the Olympics when it became apparent that many of the real competitors were pharmacologists, not athletes.

Although we are (at least temporarily) coming out of a really nasty COVID surge, don't kid yourselves. This thing isn't done with us. Experts are predicting that this could be the "end of it." Sorry, but I don't buy it. Why?

Spoiler alert – get out the anti-depressants.

Do children under five years old need COVID-19 vaccines? Answering that question should be a simple matter of comparing the risk of infection to the risks and benefits of vaccination in this age group.

“Mitigation of the observed risks of myocarditis/pericarditis and associated uncertainties will be accomplished through labeling (including warning statements about the risks of vaccine-associated myocarditis/pericarditis) and

I recently wrote an article comparing the availability and use of the two newly approved anti-COVID drugs (1) Paxlovid and molnupiravir. Bottom line: Doctors and patients voted with their scripts.

Here we go again. Entasis Therapeutics has been struggling in the public marketplace.